Advertisement


Tycel J. Phillips, MD, and Emanuele Zucca, MD, on Primary Mediastinal B-Cell Lymphoma: New Data on Observation vs Radiotherapy

2023 ASCO Annual Meeting

Advertisement

Tycel J. Phillips, MD, of City of Hope National Medical Center, and Emanuele Zucca, MD, of the Oncology Institute of Southern Switzerland and the International Extranodal Lymphoma Study Group, discuss findings from the largest prospective study of patients with primary mediastinal B-cell lymphoma. The trial data support omitting radiotherapy in patients who achieve complete metabolic response after immunochemotherapy (Abstract LBA7505).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Tycel J. Phillips, MD: What led you guys to investigate whether omission of radiation was possible? Emanuele Zucca, MD: The first issue to keep in mind is that primary mediastinal large cell lymphoma is a totally separate and particular entity which is affecting younger people in their 30 and 40 years of age, mainly white women but not just them, and is presenting with a bulky chest mass. And at the end of induction immunochemotherapy, nearly all the patient still have a residual lesion in the chest. And the fact that patient with earlier relapse or not rapid remission had this malprognosis led many investigative doctors to give to everybody consolidation radiotherapy to the mediastinal after induction immunochemotherapy. And this is increasing the risk of second cancer and delayed cardiac toxicity, both valvular and ischemic cardiac disease. This was the first part of the story. Second part is that roughly 15, 20 years ago at the NIH has been developed a regimen called dose-adjusted EPOCH-R, which was quite promising in this disease. And there were data indicating that perhaps radiotherapy was no longer needed for patients responding to immunochemotherapy. This led actually to a never-ending controversy and there are people and many countries where radiotherapy has remained in the standard, for example, in Italy or in Germany, and others, for example, just to stay in Europe, in France where radiotherapy was no longer used. And- Tycel J. Phillips, MD: That's a very good- Emanuele Zucca, MD: ... and this prompted us to design a study to address this controversy. Tycel J. Phillips, MD: No, no, that's a very, very good point. I mean, because I think as you pointed out with dose-adjusted EPOCH, I think a lot of us US investigators prefer that regimen over the ability to hopefully omit radiation, whereas we almost felt obligated with R-CHOP, so I think your study will add a lot of context to that controversy. Emanuele Zucca, MD: Yes. First, our study has a byproduct to show that standard R-CHOP given every three weeks is likely inferior to the more aggressive dose-enhanced regimens including EPOCH-R. But the main result of the study is that we can actually spare radiotherapy to the people achieving a metabolic complete response after immunochemotherapy. Tycel J. Phillips, MD: And that's any immunochemotherapy, correct? Emanuele Zucca, MD: Yes. Tycel J. Phillips, MD: Okay. Emanuele Zucca, MD: The point is that they have with PET scan a residual uptake in the residual lesions which has to be below the liver uptake. This is called Deauville score 3 and is indicating a complete metabolic response as well as lower uptakes, which are Deauville score of 1 or 2. And patients achieving a metabolic response on PET scan do not need radiotherapy according to our results. There is a very tiny benefit of radiotherapy, around at 2%, which is not translating in any superiority of overall survival. Patients achieving a complete remission at three years after study entry had 99% survival rates irrespectively of whether they got or not radiotherapy. Tycel J. Phillips, MD: That's excellent. So I think as you pointed out very clearly, it's very important to know that even if the patients actually got R-CHOP and went into remission, that you could safely omit radiotherapy if they were PET negative. Emanuele Zucca, MD: Yes. Tycel J. Phillips, MD: So what are the next steps for this study as it matures? Emanuele Zucca, MD: Which was somehow surprising us during the study was that we had a very low rate of events. However, the rate of complete remission by PET at the end of immunochemotherapy was only about 50%. So I am expecting that there is a portion of patients with partial remission in this PET scan evaluation who are actually with no longer active tumor, but just is a problem of very high sensitivity of modern PET scans. And for this reason, we will investigate whether we can use liquid biopsy to see whether a partial response is in need of additional radiotherapy or not. That is what we are discussing for the future. Tycel J. Phillips, MD: No, that would be actually a phenomenal study to do, because I think we've all seen areas with partial responses, especially with PET scans and areas that we can't reach and sort of question whether that's actually true responses, so to be able correlate that with liquid biopsies would be a monumental step forward for all of us to better understand these diseases. I think overall, I mean I think this contribution of this abstract is very helpful for, as you already mentioned, a very young patient population. One last question before we wrap up. As far as the side effect profile, have you guys noticed anything in the short term in the group that was randomized to radiation versus those that did not get radiation? Emanuele Zucca, MD: There is no data indicating that there is a subset of patients who are likely experiencing a different outcome. I think that the study has a very simple take-home message, which is no radiotherapy for those in complete remission, and also, thus far it is too early for addressing delayed toxicity, but [inaudible 00:06:49] we had six serious events with three serious cardiac events and three second cancers, all of them in the radiation therapy arm. Tycel J. Phillips, MD: Interesting. Emanuele Zucca, MD: Which is supporting even more the study results. Tycel J. Phillips, MD: No, I agree. Thank you. Great study, great presentation. And I look forward to further maturation of the study data. I'm assuming we all do and I appreciate you taking the time to talk to me this afternoon. Emanuele Zucca, MD: It was nice to meet you. Tycel J. Phillips, MD: Yeah, thank you. Emanuele Zucca, MD: Bye.

Related Videos

Colorectal Cancer

Cathy Eng, MD, and Thejus Jayakrishnan, MD, on Colorectal Cancer: Metabolomic Differences in Young-Onset vs Average-Onset Disease

Cathy Eng, MD, of Vanderbilt-Ingram Cancer Center, and Thejus Jayakrishnan, MD, of the Cleveland Clinic Taussig Cancer Institute, discuss significant differences in the citrate cycle, a core pathway of cellular metabolism associated with colorectal cancer. Metabolomic differences impacted by environmental exposures (arginine biosynthesis and dietary red meat) were also noted, suggesting possible links with younger age of onset in this disease (Abstract 3510).

Lymphoma

Jennifer L. Crombie, MD, on DLBCL: Real-World Outcomes With Novel Therapies in Relapsed or Refractory Disease

Jennifer L. Crombie, MD, of Dana-Farber Cancer Institute, discusses the historically poor outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Her study examined real-world data on the use of novel therapies in this population and found that outcomes with second- and third-line regimens of polatuzumab vedotin-piiq plus bendamustine and rituximab and tafasitamab plus lenalidomide remain suboptimal, with worse outcomes particularly after chimeric antigen receptor T-cell therapy (Abstract 7552).

Prostate Cancer

Alberto Bossi, MD, on Prostate Cancer: PEACE-1 Trial Findings on Radiotherapy Plus Systemic Treatment

Alberto Bossi, MD, of Institut Gustave Roussy, discusses phase III findings showing that combining prostate radiotherapy with systemic treatment did not improve overall survival in men with de novo metastatic castration-sensitive prostate cancer and low metastatic burden. However, best outcomes (radiographic progression–free-survival and overall survival) were observed in men receiving the standard of care plus abiraterone acetate plus prednisone with radiotherapy (Abstract LBA5000).

Lymphoma

Muhit Özcan, MD, on DLBCL: Early Results on Zilovertamab Vedotin

Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses phase II findings from the waveLINE-004 study. It showed that the antibody-drug conjugate zilovertamab vedotin had clinically meaningful antitumor activity in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who experienced disease progression after, or have been ineligible for, autologous stem cell transplantation and/or chimeric antigen receptor T-cell therapy (Abstract 7531).

Gynecologic Cancers

Bobbie J. Rimel, MD, and Kathleen N. Moore, MD, on Ovarian Cancer: New Findings on Mirvetuximab Soravtansine vs Chemotherapy

Bobbie J. Rimel, MD, of Cedars-Sinai Medical Center, and Kathleen N. Moore, MD, of the Stephenson Oklahoma Cancer Center at the University of Oklahoma, discuss phase III results from the MIRASOL trial, which showed that mirvetuximab soravtansine-gynx prolonged overall survival vs investigator’s choice chemotherapy in patients with platinum-resistant ovarian cancer with high folate receptor-alpha expression. The findings suggest a new standard of care for this disease (Abstract LBA5507).

Advertisement

Advertisement




Advertisement